N-(3,3-dimethylbutyryl)-L-valine | 228402-73-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3,3-dimethylbutyryl)-L-valine
• 英文别名: (2S)-2-(3,3-dimethylbutanoylamino)-3-methylbutanoic acid
• CAS: 228402-73-1
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: AUFSKGUKHMFGHF-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3,3-dimethylbutyryl)-L-valine 在 palladium on activated charcoal 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-(3,3-dimethylbutyryl)-L-valyl-L-valine
  参考文献：
  名称：

  Simplified Pepstatins:  Synthesis and Evaluation of N-Terminally Modified Analogues

  摘要：

  The promising strategy of gastric ulcer healing with perorally administered epidermal growth factor (EGF) is so far strongly limited by the pepsinic degradation of this therapeutic polypeptide in the stomach. The incorporation of EGF in a bioadhesive polymer-pepsin inhibitor conjugate used as drug carrier matrix, however, might provide sufficient protection toward pepsinic degradation. The synthesis of appropriate pepsin inhibitors represents a prerequisite for the development of such polymer-inhibitor conjugates. The presented study demonstrates that modifications at the N-terminus of simplified analogues of pepstatin which can be synthesized in a simple and straight way result only in slight variations of the inhibitory activity. These analogues display only 10-fold reduced-inhibitory activity, compared to pepstatin A, when bearing a greater N-terminal group like isovaleryl, Boc, or Cbz. Compounds which are substituted at the N-terminus by a shorter N-acyl group like propionyl or cyclopropylcarbonyl show further reduced activity (0.01, compared to pepstatin A). The presence of an amide or a urethane moiety at the N-terminus has no considerable effect on enzyme inhibition. Therefore, the N-terminus of these analogues is able to be modified forming a covalent bond to various bioadhesive polymers via a suitable functionality.

  DOI：

  10.1021/jm9807306
• 作为产物：
  描述：

  L-缬氨酸 、 3,3-二甲基丁酰氯 在 magnesium oxide 作用下， 以 乙醚 、 水 为溶剂， 生成 N-(3,3-dimethylbutyryl)-L-valine
  参考文献：
  名称：

  Simplified Pepstatins:  Synthesis and Evaluation of N-Terminally Modified Analogues

  摘要：

  The promising strategy of gastric ulcer healing with perorally administered epidermal growth factor (EGF) is so far strongly limited by the pepsinic degradation of this therapeutic polypeptide in the stomach. The incorporation of EGF in a bioadhesive polymer-pepsin inhibitor conjugate used as drug carrier matrix, however, might provide sufficient protection toward pepsinic degradation. The synthesis of appropriate pepsin inhibitors represents a prerequisite for the development of such polymer-inhibitor conjugates. The presented study demonstrates that modifications at the N-terminus of simplified analogues of pepstatin which can be synthesized in a simple and straight way result only in slight variations of the inhibitory activity. These analogues display only 10-fold reduced-inhibitory activity, compared to pepstatin A, when bearing a greater N-terminal group like isovaleryl, Boc, or Cbz. Compounds which are substituted at the N-terminus by a shorter N-acyl group like propionyl or cyclopropylcarbonyl show further reduced activity (0.01, compared to pepstatin A). The presence of an amide or a urethane moiety at the N-terminus has no considerable effect on enzyme inhibition. Therefore, the N-terminus of these analogues is able to be modified forming a covalent bond to various bioadhesive polymers via a suitable functionality.

  DOI：

  10.1021/jm9807306

文献信息

• Methods of treating alzheimer's disease
  申请人：Schostarez Heinrich

  公开号：US20050130941A1

  公开（公告）日：2005-06-16

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R 1 -R 9 are defined herein.

  本发明涉及使用式(I)中变量R1-R9所定义的肼化合物治疗阿尔茨海默病和其他疾病，抑制β-分泌酶酶活性，抑制A beta肽在哺乳动物体内的沉积。
• Antiretrovirale hydrazinderivate
  申请人：CIBA-GEIGY AG

  公开号：EP0604368A1

  公开（公告）日：1994-06-29

  Beschrieben werden Verbindungen der Formel worin R₁ und R₉ unabhängig voneinander Wasserstoff, Acyl, unsubstituiertes oder substituiertes Alkyl; Sulfo; oder durch unsubstituiertes oder substituiertes Alkyl, Aryl oder Heterocyclyl substituiertes Sulfonyl bedeuten, mit der Massgabe, dass höchstens einer der Reste R₁ und R₉ Wasserstoff bedeutet; und R₂ und R₈ jeweils unabhängig voneinander Wasserstoff oder unsubstituiertes oder substituiertes Alkyl bedeuten; R₃ und R₄ unabhängig voneinander Wasserstoff, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl oder Aryl bedeuten; R₅ Acyloxy bedeutet; R₆ Wasserstoff bedeutet; und R₇ unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl oder Aryl bedeutet; sowie Salze der genannten Verbindungen, sofern salzbildende Gruppen vorliegen; diese Verbindungen zeigen antiretrovirale Wirksamkeit.

  式中的化合物 其中 R₁ 和 R𠢙 相互独立地为氢、酰基、未取代或取代的烷基；磺酰基；或被未取代或取代的烷基、芳基或杂环基取代的磺酰基，但 R₁ 和 R𠢙 自由基中最多有一个是氢；R₂ 和 R₈ 相互独立地为氢或未取代或取代的烷基； R₃ 和 R₄ 各自独立地为氢、未取代或取代的烷基、未取代或取代的环烷基或芳基； R₅ 表示酰氧基； R₆ 表示氢； R₇ 表示未取代或取代的烷基、未取代或取代的环烷基或芳基； 以及上述化合物的盐类，只要存在成盐基团；这些化合物具有抗逆转录病毒活性。
• METHODS OF TREATING ALZHEIMER'S DISEASE
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1392315A1

  公开（公告）日：2004-03-03
• IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD
  申请人：Nektar Therapeutics

  公开号：US20210292425A1

  公开（公告）日：2021-09-23

  Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.
• US5753652A
  申请人：——

  公开号：US5753652A

  公开（公告）日：1998-05-19